Epilepsy
Education on Epilepsy and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Epilepsy and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Epilepsy?
Epilepsy is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Neurological conditions affect the brain, spinal cord, or nerves. The patent explores links between AAT levels and certain neurodegenerative processes.
What Mark Egly's patent discusses
Epilepsy is a neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions. Epilepsy is associated with abnormal electrical activity in the brain. As demonstrated by an eHealthMe study, neutrophil count is increased in patients with epilepsy. By reducing neutrophil count using AAT, epilepsy and epileptic seizures may be managed. Due to the link between AATD and epilepsy, in one embodiment AAT may be used to treat, control, or prevent epilepsy in patients, either with or without known AATD. A diagnosis of epilepsy may prompt a medical provider to test a patient for AATD. Alternatively, a patient diagnosed with epilepsy may seek genetic testing for AATD through an independent genetic testing company such as 23andMe or geneology.com, a pharmaceutical company supplied test kit or other private methods available. A method for treating a patient suffering from epilepsy with AAT begins with the step of determining if the patient is AAT deficient or has lower AAT levels without being AATD. Determining if the patient is AAT deficient or has lower AAT levels without being AATD proceeds as previously described in this disclosure in t…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Epilepsy, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Epilepsy, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: